ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,306.49
0.67%
Dow Jones
42,635.20
0.00%
Gold vs US Dollar
2,675.025
0.95%
Brent Oil
76.82
1.09%
Bitcoin
93,968.59
-1.14%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Prelude Therapeutics Inc (PRLD) Share Price

PRLD Prelude Therapeutics Inc

1.14
0.00 (0.00%)
09 Jan 2025 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Prelude Therapeutics Inc NASDAQ:PRLD NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.00 0.00 1.14 1.13 1.23 0.00 0.00   00:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -121.83M -2.2137 -0.51 62.74M
 Type  Size  Price  Time  Units 
   0.00  
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore PRLD News
07/01/202521:15EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
03/01/202512:41EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
02/01/202521:09EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
20/12/202412:35EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
20/12/202412:33EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
11/12/202412:45EDGAR2Form 8-K - Current report
11/12/202412:30GLOBEPrelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Period
Draw mode
Data Downloads for PRLD

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Prelude Therapeutics Inc Articles

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads